<DOC>
	<DOCNO>NCT01614301</DOCNO>
	<brief_summary>A prospective phase I consecutive phase II , twoarm , randomize multi-center trial temsirolimus combination pioglitazone , etoricoxib metronomic low-dose trofosfamide versus dacarbazine ( DTIC ) patient advance melanoma Phase I : To determine dose temsirolimus use phase II part study Phase II : To determine overall survival Secondary objective - To evalulate response rate - To evaluate time progression ( TTP ) - To evalulate time partial response ( time PR well ) ( TPR ) - To evaluate quality life - To evaluate tolerability safety</brief_summary>
	<brief_title>Phase I Consecutive Phase II , Two-arm , Randomized Multi-center Trial Patients With Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Trofosfamide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Etoricoxib</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>At least 18 year age Must able adhere study visit schedule protocol requirement . Must histologically diagnose metastatic melanoma LDH level &gt; 0.8 ULN Measurable lesion Subjects must receive study medication firstline therapy . Preceeding adjuvant therapy allow . BRAF V600 mutation analysis Sufficient bone marrow function : neutrophil ≥ 2x109/l , hemoglobin ≥10 g/dl , platelet ≥ 100x109/l Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 ( see Post Text Supplement 3 ) . Required laboratory result : 1 . Liver function : Total bilirubin &lt; 1.5 time upper limit local institution ( ULN ) , SGPT , SGOT ≤ 2.5 time upper limit local institution 2 . Renal function : serum creatinine ≤ 1.5 ULN 3 . PTINR/PT &lt; 1.5 ULN Normal cardiac function Patients prior thrombembolic event adequate anticoagulation Life expectancy least 3 month Written inform consent patient prior screen procedure Patient must available treatment followup Adequate contraception woman capable bear child men partner capable bearing child ( combine oral contraceptive , hormonereleasing intrauterine contraceptive device , hormonal contraceptive implant , hormonal contraceptive injectables , surgical sterilization ) Any previous surgery must take place 4 week prior inclusion Previous radiation therapy must involve less 25 % bone marrow , must complete 4 week prior inclusion . For patient control diabetes mellitus glucose level monitor continuously treat diabetologist inform study participation patient . Patients wildtype BRAF Documented brain metastasis unless patient complete successful local therapy central nervous system metastases corticosteroid least 4 week enrollment . Patients require vitamin K antagonist except low dose Patients bladder cancer bladder cancer medical history , patient risk factor bladder cancer ( exposure aromatic amine heavy tobacco smoker ) , macrohematuria unknown origin Prior history stroke Known hypersensitivity study drug excipients Active infection &gt; grade 2 NCICTC version 4.0 Known diagnosis HIV , hepatitis B , hepatitis C infection . Severe , unstable , uncontrolled medical disease would confound diagnosis evaluation require protocol , include cardiac insufficiency ( NYHA I IV ) uncontrolled diabetes include diabetic ketoacidosis , chronic hepatic renal disease , active uncontrolled infection chronic inflammatory intestinal disease , autoimmune disease , peripheral arterial disease , verify coronary heart disease , cerebrovascular disease , acute peptic ulcer acute gastrointestinal bleeding . Prior radiation therapy &gt; 25 % bone marrow Regular blood transfusion Treatment experimental substance within 30 day study start Prior immunotherapy ipilimumab , vaccination , Braf inhibitor Participation another clinical trial within 30 day study start trial Unwilling unable comply protocol Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform 7 day prior start treatment . Patients seizure disorder require medication ( steroids antiepileptic ) Patients evidence history bleed diathesis Patients undergoing renal dialysis Major surgery within 4 week prior start study incomplete wound heal Drug alcohol abuse Psychological social condition may interfere patient participation study evaluation study result . Known ( time entry ) gastrointestinal disorder , include malabsorbtion active gastric ulcer , present extent might interfere oral intake absorption study medication Patients undergoing dialysis creatinine clearance &lt; 30 mL per minute , define accord MDRD Patients medically uncontrolled hypertension ( RR continuously &gt; 140/90 mm Hg ) Any previous concurrent malignancy cancer unless curatively treat &gt; 3 year prior study entry except cervical carcinoma situ adequate basal cell carcinoma Any urothelial cell carcinoma medical history Patients experience bronchospasm , acute rhinitis , nasal polyp , angioneurotic oedema , urticaria , allergic type reaction acetylsalicylic acid NSAIDs include COX2 ( cyclooxygenase2 ) inhibitor Patients BRAF V600 mutant metastatic melanoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>advanced Melanoma</keyword>
</DOC>